Mammary Cell News Volume 7.03 | Jan 29 2015

​Gd-Metallofullerenol Nanomaterial as Non-Toxic Breast Cancer Stem Cell-Specific Inhibitor
Scientists provide definitive evidence that the metallofullerenol nanomaterial ​Gd@C₈₂(OH)₂₂, while essentially not toxic to normal mammary epithelial cells, possesses intrinsic inhibitory activity against triple-negative breast cancer cells. [Nat Commun] Full Article

Carbonic Anhydrase IX Promotes Myeloid-Derived Suppressor Cell Mobilization and Establishment of a Metastatic Niche by Stimulating G-CSF Production
Researchers show that carbonic anhydrase IX (CAIX) is indispensable for the production of G-CSF by hypoxic breast cancer cells and tumors. They demonstrate that CAIX expression in the tumor is required for the G-CSF-driven mobilization of granulocytic myeloid-derived suppressor cells to the breast cancer lung metastatic niche. [Cancer Res] Abstract

Three-Dimensional Microenvironment Confers Enhanced Sensitivity to Doxorubicin by Reducing p53-Dependent Induction of Autophagy
Investigators evaluated the microenvironmental control of human breast cancer cells responses to doxorubicin (DOXO) using the three-dimensional (3D) laminin-rich extracellular matrix cell culture model. Under 3D culture conditions, MCF-7 cells displayed drastic morphological alterations, a decrease in proliferation and elevated sensitivity to DOXO. [Oncogene] Abstract

Cell Surface Heparan Sulfate Proteoglycans Control Adhesion and Invasion of Breast Carcinoma Cells
The MDA-MB231 human breast carcinoma cell line was exposed to exogenous glycosaminoglycans and changes in cell behavior monitored by western blotting, immunocytochemistry, invasion and collagen degradation assays. [Mol Cancer] Abstract | Full Article

miR-29b Defines the Pro-/Anti-Proliferative Effects of S100A7 in Breast Cancer
Investigators show that S100A7 significantly downregulates the expression of miR-29b in estrogen receptor (ER)-positive breast cancer cells, and significantly upregulates miR-29b in ER-negative cells. [Mol Cancer] Abstract | Full Article

The Telomerase Inhibitor Imetelstat Alone, and in Combination with Trastuzumab, Decreases the Cancer Stem Cell Population and Self-Renewal of HER2⁺ Breast Cancer Cells
Scientists investigated the effects of a telomerase antagonistic oligonucleotide, imetelstat, on cancer stem cell (CSC) and non-CSC populations of HER2⁺ breast cancer cell lines. [Breast Cancer Res Treat] Abstract

Breast Cancer Cells Promote a Notch-Dependent Mesenchymal Phenotype in Endothelial Cells Participating to a Pro-Tumoral Niche
Researchers show that co-injection of endothelial cells (ECs) and tumor cells in NOD/SCID mice significantly enhanced tumor growth in vivo with tumor-associated ECs expressing mesenchymal markers while maintaining their intrinsic endothelial trait. [J Transl Med] Abstract | Full Article

The Na⁺/HCO₃^– Co-Transporter SLC4A4 Plays a Role in Growth and Migration of Colon and Breast Cancer Cells
In MDA-MB-231 breast cancer cells expressing high levels of SLC4A4 compared to LS174 cells, SLC4A4 knockdown had a strong impact on cell proliferation, migration, and invasion. [J Cell Physiol] Abstract

Calycosin and Genistein Induce Apoptosis by Inactivation of HOTAIR/p-Akt Signaling Pathway in Human Breast Cancer MCF-7 Cells
Both calycosin and genistein inhibited proliferation and induced apoptosis in MCF-7 breast cancer cells, especially after treatment with calycosin. Treatment of MCF-7 cells with calycosin or genistein resulted in decreased phosphorylation of Akt, and decreased expression of its downstream target, HOX transcript antisense RNA (HOTAIR). [Cell Physiol Biochem] Full Article

CLINICAL RESEARCH

Olaparib Monotherapy in Patients with Advanced Cancer and a Germline BRCA1/2 Mutation
Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2)-associated breast and ovarian cancers. Researchers evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated cancers. [J Clin Oncol] Full Article

The Prognostic and Predictive Value of Tregs and Tumor Immune Subtypes in Postmenopausal, Hormone Receptor-Positive Breast Cancer Patients Treated with Adjuvant Endocrine Therapy: A Dutch TEAM Study Analysis
Researchers defined the prognostic and predictive value of tumor immune markers and the tumor immune profile in HR⁺ breast cancer, treated with different endocrine treatment regimens. [Breast Cancer Res Treat] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

New Animal Models Faithfully Reproduce the Tumor of Each Patient
A team from the Catalan Institute of Oncology and Bellvitge Biomedical Research Institute has developed new animal models that reproduce faithfully the evolution and malignancy of different human tumors. [Bellvitge Biomedical Research Institute] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Director (California Institute for Regenerative Medicine)

Postdoctoral Positions – Cancer Bioengineering and Cancer Biology (University of Minnesota)

Director of Research (Dr. Susan Love Research Foundation)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Principal Investigator – Human Cancer Genomics and Mouse Modeling (Lunenfeld-Tanenbaum Research Institute)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Postdoctoral Position – Experimental Breast Cancer Therapy (University of Pennsylvania)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.